December 22, 2014Morningside Venture (VI) Investments LTD • April 24th, 2015 • Pharmaceutical preparations
The undersigned, a securityholder, officer and/or director of Aduro BioTech, Inc., a Delaware corporation (the “Company”), understands that Merrill Lynch, Pierce, Fenner & Smith Incorporated (“Merrill Lynch”) and Leerink Partners LLC (“Leerink”) propose to enter into an Underwriting Agreement (the “Underwriting Agreement”) with the Company providing for the public offering (“Public Offering”) of shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). In recognition of the benefit that such an offering will confer upon the undersigned as a securityholder, officer and/or director of the Company, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with each underwriter to be named in the Underwriting Agreement that, during the period beginning on the date hereof and ending on the date that is 180 days from the date of the Underwriting Agreement (the “Lock-Up Period”), the unders
JOINT FILING AGREEMENTJoint Filing Agreement • February 16th, 2021 • Morningside Venture (VI) Investments LTD • Pharmaceutical preparations
The undersigned, being duly authorized thereunder, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule 13D (including amendments thereto) jointly on behalf of each such party.
JOINT FILING AGREEMENTJoint Filing Agreement • May 24th, 2019 • Morningside Venture (VI) Investments LTD • Pharmaceutical preparations
The undersigned, being duly authorized thereunder, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule 13D (including amendments thereto) jointly on behalf of each such party.
JOINT FILING AGREEMENTJoint Filing Agreement • September 15th, 2017 • Morningside Venture (VI) Investments LTD • Pharmaceutical preparations
The undersigned, being duly authorized thereunder, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule 13D (including amendments thereto) jointly on behalf of each such party.
JOINT FILING AGREEMENTJoint Filing Agreement • April 24th, 2015 • Morningside Venture (VI) Investments LTD • Pharmaceutical preparations
The undersigned, being duly authorized thereunder, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule jointly on behalf of each such party.
JOINT FILING AGREEMENTJoint Filing Agreement • March 22nd, 2019 • Morningside Venture (VI) Investments LTD • Pharmaceutical preparations
The undersigned, being duly authorized thereunder, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule 13D (including amendments thereto) jointly on behalf of each such party.
